Following data analysis based on the mutational status of IGHV, a similar frequency pattern was observed: The frequency of CD14+HLA-DRlow/− MDSCs was significantly higher in the IGHV-unmutated (U-CLL) and IGHV-mutated (M-CLL) CLL patients when compared with the control (both P<0.0001), and these MDSCs were significantly more elevated in the U-CLL patients compared with the M-CLL patients (P=0.0019) (Fig. 2D). This evidence concerns the gene CD14 and B-cell chronic lymphocytic leukemia.